Table 3

Distribution of consolidation therapies (third cycle of chemotherapy, autologous SCT, or allo-SCT), applied to patients in donor and no donor groups

Type of therapyGroup of patients
DonorNo donor
All patients 326 599 
Chemotherapy, n (%)* 55 (17) 398 (65) 
Autologous SCT, n (%) 3 (1) 165 (28) 
Allogeneic SCT, n (%) 
    HLA-identical sibling 268 (82) 
    Unrelated donor 40 (7) 
    Mismatched family donor 5 (1) 
Type of therapyGroup of patients
DonorNo donor
All patients 326 599 
Chemotherapy, n (%)* 55 (17) 398 (65) 
Autologous SCT, n (%) 3 (1) 165 (28) 
Allogeneic SCT, n (%) 
    HLA-identical sibling 268 (82) 
    Unrelated donor 40 (7) 
    Mismatched family donor 5 (1) 

SCT indicates stem cell transplantation; HLA human leukocyte antigen.

*Third cycle of chemotherapy.

†Preceded by high-dose cytotoxic therapy.

Close Modal

or Create an Account

Close Modal
Close Modal